Patents and Patients, Cipla, Video
Register as a Premium Educator at hbsp.harvard.edu, plan a course, and save your students up to 50% with your academic discount.
Publication Date:
February 27, 2007
Source:
Harvard Business School
The head of Cipla, a $325-million-dollar Indian pharmaceutical company and seller of low-cost AIDS drugs to South Africa, must decide what to do about Cipla’s future. With India poised to enforce international patents in only two years, much of Cipla’s product line could become unsalable (give that it is based on product patents protected in industrialized countries). Describes Cipla’s role in forcing global pharmaceutical companies to lower their prices for AIDS drugs.
If you’d like to share this PDF, you can purchase copyright permissions by increasing the quantity.
Copyright © 2021 Harvard Business School Publishing. All rights reserved. Harvard Business Publishing is an affiliate of Harvard Business School.
Patents and Patients, Cipla, Video
Research & References of Patents and Patients, Cipla, Video|A&C Accounting And Tax Services
Source